S-H. Lee - Samsung Medical Center, Sungkyunkwan University School of Medicine

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 60 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

A. Passaro,J. Wang,Y. Wang,S.-H. Lee,B. Melosky,J.-Y. Shih,J. Wang,K. Azuma, O. Juan-Vidal,M. Cobo, E. Felip,N. Girard,

Annals of oncology : official journal of the European Society for Medical Oncologyno. 1 (2024): 77-90

引用6浏览0WOS引用

5MO Effect of amivantamab dose interruptions on efficacy and safety of first-line amivantamab plus lazertinib in EGFR-mutant advanced NSCLC: Exploratory analyses from the MARIPOSA study

M.R. García Campelo,B.C. Cho, N. Girard, S. Lu, H. Yoshioka, J-S. Lee,S-H. Lee, B. Liu, M.A.N. Sendur, B. Besse, A. Spira, E. Felip,

ESMO Open (2024)

引用0浏览0引用

VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC

M. J. Hochmair, K. Vermaelen, G. Mountzios, E. Carcereny, C. Dooms,S. -h. Lee, E. M. Morocz, T. Kato, T-e. Ciuleanu,G. Dy, M. B. M. C. S. Parente,K. J. O'Byrne,

ANNALS OF ONCOLOGY（2024）

引用0浏览0引用

Socio-economic factors and medical conditions affecting regular stomach cancer screening in Korea: a retrospective longitudinal study using national public health data for 11 years

J. -y. Kim, J. Y. Hong,S. M. Kim, K. H. Ryu,D. S. Kim,S. H. Lee, J. H. Na,H. H. Cho,J. Yu,J. Lee

PUBLIC HEALTH (2024): 70-77

引用0浏览0WOS引用

Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis

J-Y. Shih, J. Wang, Y. Wang, J. Wang,S-H. Lee, K. Azuma, T. Takahashi,J-L. Tan,C. C. Lin, S. Ganguly, V. H. F. Lee, P-L. Chu,

ANNALS OF ONCOLOGY (2023): S1661-S1662

引用0浏览0引用

2330P Pre-test prediction of multiple druggable mutations based on H&E image artificial intelligence (AI) analysis may enable more efficient clinical workflow for treatment decisions in non-small cell lung cancer (NSCLC)

J. Lee, S. Park,S-H. Lee,Y-L. Choi,Y-D. Choi, M-G. Noh,J. Park, S. Shin,T. Lee,H. Song, J. Ro, J. Moon,

Annals of Oncology (2023): S1189-S1190

引用0浏览0引用

Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Single-Arm, Phase II Multi-Center Trial

S. Park,H. K. Ahn,S. Lee,Y. J. Min,H. A. Jung, J. -M. Sun,S-H. Lee, J. S. Ahn,M. -J. Ahn, J. B. Lee,S. M. Kim,H. R. Kim,

Journal of Thoracic Oncologyno. 11 (2023): S148-S149

引用0浏览0引用

LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)

J.D. Spicer, S. Gao,M. Liberman,T. Kato,M. Tsuboi,S-H. Lee,K-N. Chen,C. Dooms, M. Majem, E. Eigendorff, G. Martinengo,O. Bylicki,

The New England journal of medicine（2023）

引用0浏览0WOS引用

1371P First-line alectinib vs. brigatinib in advanced metastatic NSCLC with ALK rearrangement: Real-world data

Y.K. Jeon,S. Park, H.A. Jung,J-M. Sun,S-H. Lee,J.S. Ahn,M-J. Ahn

Annals of Oncology (2023): S787

引用0浏览0引用

Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study

H. A. Jung, S. Park,S. -H. Lee,J. S. Ahn,M. -J. Ahn,J. -M. Sun

ESMO OPENno. 6 (2023): 102068

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn